ClinicalTrials.gg
CompletedNCT02094534Updated Jul 6, 2017Results posted

A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

A Phase 2 interventional study of ORMD-0801 Capsules and Placebo in Diabetes Mellitus Type 1, sponsored by Oramed, Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-07-06.

Sponsored by Oramed, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
786th of 1,242
25 · median 40
Started
2014
with 56 others
Phase 2
188 of 1,458
24 open now
Registered
566th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 786th largest by enrollment of the 1,242 interventional ones that give a count, is one of 57 that started in 2014, is one of 188 in phase 2, and was the 566th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This will be a prospective, randomized, double-blind, placebo controlled study. Patients with established Type 1 diabetes will be eligible for entry into the study. Eligible patients will be screened and those who fulfill all inclusion/exclusion criteria will be admitted to the inpatient unit no fewer than 2 days and no more than 7 days after Screening. Patients will report to the inpatient unit at 6 a.m. and outfitted with a continuous glucose monitoring (CGM) device. Patients will be given standardized meals and snacks for the duration of their inpatient visit.

Read the detailed description

For the first 3 days, patients will be dosed with placebo 45 minutes prior to each of the day's 3 meals to establish baseline insulin requirements. Patients will be dosed with exogenous insulin according to their normal sliding scale and each patient's daily insulin requirement will be documented. The average daily insulin requirements during the 3 day run-in period will constitute the patient's baseline insulin level.

Following the 3 day run-in, the CGM device will be detached, its data download, and the patient refitted with the CGM with a fresh cannula for continued monitoring during the 7-day treatment period.

Patients will be randomized 2:1 to receive ORMD-0801 or placebo for the 7-day double-blind treatment period.

03

Conditions studied

  • Diabetes Mellitus Type 1

Keywords

  • Diabetes type 1
  • Oral Insulin
  • Safety
  • Tolerability
  • Phase 2a
  • Randomized
  • Blinded
  • Parallel
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and Females age 18 to 55 years old, inclusive.
  • Patients must be willing and able to sign .
  • Documented history of Type 1 Diabetes for at least 6 months
  • Females of must have a negative serum pregnancy test at screening and a negative urinary screening test following admission to the inpatient unit

Exclusion criteria

Exclusion Criteria:

  • Presence of any endocrine disease according to the Investigator (euthyroid patients on replacement therapy will be included if the dosage of thyroxine is stable for at least six weeks prior to Screening)
  • Fasting plasma glucose >260 mg/dL at the end of run-in
  • Evidence of unawareness of hypoglycemia with a documented plasma glucose ≤50 mg/dL in the absence of symptoms of hypoglycemia
  • Presence of any clinically significant condition that might interfere with the evaluation of study medication (i.e., significant renal, hepatic, gastrointestinal (GI), cardiovascular (CV), immune disease).
  • Presence or history of cancer within the past five years with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer
  • Laboratory abnormalities at screening including:
  • Positive pregnancy test in females of (at screening and Day -3 of Visit 2)
  • Abnormal serum thyrotropin (TSH) levels >1.5X (ULN)
  • Positive test for surface antigen and/or antibody
  • Positive test for
  • Any relevant abnormality interfering with the efficacy or the safety assessments during study drug administration
  • Use of the following medications:

    o History of use of aprotinin at any time prior to the screening visit (e.g., Trasylol, any type or dose)

  • Administration of thiazolidinedione [e.g., (Actos (pioglitazone) and Avandia (rosiglitazone)] treatment within 3 months prior to randomization.
  • Administration of thyroid preparations or thyroxine (except in patients on stable replacement therapy) within 6 weeks prior to screening visit
  • Administration of systemic long-acting within two months or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids (if daily dosage is > 1,000 μg equivalent beclomethasone) within 30 days prior to screening visit
  • Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and inhaled steroids (as discussed above), beta blockers (with the exception of beta blocker ophthalmic solutions for glaucoma or ocular hypertension), and or immunomodulating agents
  • History of severe or multiple allergies, or known allergy to soy or aprotinin.
  • History of tobacco or nicotine use within 10 weeks prior to screening
  • Patient is on a weight loss program and is not in the maintenance phase, or patient that started weight loss medication (e.g., orlistat or sibutramine) within 8 weeks prior to screening
  • Pregnancy or breast-feeding
  • Patient has a screening visit systolic blood pressure of ≥165 mmHg or diastolic blood pressure of ≥100 mmHg.
  • Patient is, at the time of consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by >3 drinks per day or >14 drinks per week, or binge drinking)
  • Elevated liver enzymes ( (ALT), alanine aminotransferase (AST), alkaline phosphatase) greater than 2 times the upper limit of normal (ULN) at Screening
  • Very high triglyceride level (>600 mg/dL) at Screening
  • Any clinically significant (ECG) abnormality at screening or cardiovascular disease. Clinically significant cardiovascular disease will include:
  • history of stroke, , or myocardial infarction within 6 months prior to screening,
  • history of or currently have New York Heart Associate Class II-IV heart failure prior to screening, or
  • uncontrolled hypertension defined as (duplicate seated reading) blood pressure ≥165 mmHg (systolic) or ≥100 mmHg (diastolic) at screening or at Visit 2.
  • History of gastrointestinal disorders (e.g. hypochlorhydria) with the potential to interfere with drug absorption
  • At the Principal Investigator's discretion, any condition or other factor that is deemed unsuitable for patient enrollment into the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    ORMD-0801 Capsules

    API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801

    Biological: ORMD-0801 Capsules

  • Placebo comparator
    Placebo

    Fish oil in capsules, identical in appearance to ORMD-0801

    Other: Placebo

Interventions

  • API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.

    Also known as: Oral Insulin

  • OtherPlacebo

    Fish oil capsules, identical in appearance to the experimental intervention.

    Also known as: Fish Oil

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements

    Change from baseline (Run-in Average) to treatment days 6 and 7 (average of day 6 and 7) in exogenous insulin requirements in patients treated with ORMD-0801 compared to patients treated with placebo.

    Time frame: Baseline:Run-In Average (run in days 1-7), and treatment (day 6 and day 7)

Secondary outcomes

  1. Mean Nighttime, Daytime, and Fasting Glucose Levels

    Mean glucose levels (by continuous glucose monitoring (CGM)) in Type 1 diabetes patients treated with ORMD-0801, compared to the mean glucose levels (by continuous glucose monitoring) for patients treated with placebo.

    Time frame: last two days (day 6 and day 7, averaged)

07

Results

Posted Jul 6, 2017

Participant flow

All subjects took all doses of intervention.

Participant flow — Overall Study
MilestoneORMD-0801Placebo
Started1510
Completed1510
Not completed00

Outcome measures

PrimaryChange From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements

Change from baseline (Run-in Average) to treatment days 6 and 7 (average of day 6 and 7) in exogenous insulin requirements in patients treated with ORMD-0801 compared to patients treated with placebo.

Time frame:
Baseline:Run-In Average (run in days 1-7), and treatment (day 6 and day 7)
Reported as:
Mean · mg/dL
Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements
mg/dLORMD-0801Placebo
Total Exogenous Insulin Usage-2.09 ± 10.9362.83 ± 12.716
Basal Exogenous Insulin Usage-1.92 ± 7.517-1.10 ± 10.423
Bolus Exogenous Insulin Usage-0.18 ± 10.3103.93 ± 6.541
SecondaryMean Nighttime, Daytime, and Fasting Glucose Levels

Mean glucose levels (by continuous glucose monitoring (CGM)) in Type 1 diabetes patients treated with ORMD-0801, compared to the mean glucose levels (by continuous glucose monitoring) for patients treated with placebo.

Time frame:
last two days (day 6 and day 7, averaged)
Reported as:
Mean · mg/dL
Mean Nighttime, Daytime, and Fasting Glucose Levels
mg/dLORMD-0801Placebo
Mean nighttime levels by CGM137.65 ± 31.311133.17 ± 23.321
Mean daytime glucose levels by CGM145.15 ± 18.408165.73 ± 19.372
Mean fasting glucose levels by CGM122.15 ± 32.670138.69 ± 35.295

Adverse events

Collected over Three Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ORMD-08010/15 (0%)0/15 (0%)15/15 (100%)
Placebo0/10 (0%)0/10 (0%)10/10 (100%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventORMD-0801Placebo
HypoglycemiaMetabolism and nutrition disorders15/1510/10
HyperglycemiaMetabolism and nutrition disorders13/159/10
HeadacheNervous system disorders2/151/10
Abdominal PainGastrointestinal disorders0/151/10
Back painMusculoskeletal and connective tissue disorders0/151/10
Muscle spasmsMusculoskeletal and connective tissue disorders0/151/10
Vision blurredEye disorders1/150/10
NauseaGastrointestinal disorders1/150/10
FatigueGeneral disorders1/150/10
DizzinessNervous system disorders1/150/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ORMD-0801PlaceboTotal
<=18 years000
Between 18 and 65 years151025
>=65 years000
Age, Continuous
Age, Continuous(years)ORMD-0801PlaceboTotal
Mean38.90 ± 11.93637.61 ± 9.64238.255 ± 15.343
Sex: Female, Male
Sex: Female, Male(Participants)ORMD-0801PlaceboTotal
Female358
Male12517
Region of Enrollment
Region of Enrollment(participants)ORMD-0801PlaceboTotal
United States151025
08

Study locations

1 site
  • Orange County Research Center
    Tustin, California 92780, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Aug 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2014
First posted
Mar 24, 2014
Start
Mar 2014
Primary completionActual
Aug 2014
CompletionActual
Oct 2014
Results first posted
Jul 6, 2017
Last update
Jul 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02094534
Lead sponsor
Oramed, Ltd.
Collaborators
Integrium
Responsible party
Sponsor
First posted
Mar 24, 2014
Start date
Mar 2014
Primary completion
Aug 2014
Completion
Oct 2014
Results posted
Jul 6, 2017
Last update
Jul 6, 2017

Study contacts

Miriam Kidron, Ph.D.
study director · Oramed, Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ORMD-0801

Start the discussion